BioTuesdays

Tag - H.C. Wainwright

PDS Biotechnology Logo
Markets

HCW ups PDS Biotechnology to buy; PT $6

H.C. Wainwright upgraded PDS Biotechnology (NASDAQ:PDSB) to “buy” from “neutral” with a price target of $6. The stock closed at $2.04 on Nov. 9. In March 2020, HCW downgraded PDS based on dilution, significantly reduced...

November 10, 2020
Syros-Logo
Markets

HCW ups Syros to buy; PT to $15 from $11

H.C. Wainwright upgraded Syros Pharmaceuticals (NASDAQ:SYRS) to “buy” from “neutral” and upped its price target to $15 from $11, saying the company “has turned a corner, in our opinion.” The stock closed at $6.67 on Nov...

November 4, 2020
STRATA Skin Sciences
Markets

HCW ups STRATA Skin Sciences to buy; PT $3

H.C. Wainwright upgraded STRATA Skin Sciences (NASDAQ:SSKN) to “buy” from “neutral” with a price target of $3. The stock closed at $1.24 on Nov. 2. STRATA is a medical technology company developing and marketing...

November 3, 2020
Strongbridge Biopharma Logo
Markets

HCW cuts Strongbridge Biopharma PT to $10 from $18

H.C. Wainwright reduced its price target for Strongbridge Biopharma (NASDAQ:SBBP) to $10 from $18, citing an analysis of the changing dynamics of the Cushing’s syndrome landscape because of competitor programs. The...

October 30, 2020
Catabasis Pharma
Markets

HCW cuts Catabasis Pharma to neutral; removes PT

H.C. Wainwright downgraded Catabasis Pharmaceuticals (NASDAQ:CATB) to “neutral” from “buy” and removed its price target after the company announced that the Phase 3 PolarisDMD trial testing edasalonexent in 131 patients...

October 27, 2020
Celldex Therapeutics Logo
Markets

HCW ups Celldex Therapeutics PT to $25 from $16

H.C Wainwright raised its price target for Celldex Therapeutics (NASDAQ:CLDX) to $25 from $16, citing three differentiated programs that are now in the clinic. The stock closed at $15.76 on Oct. 16. “As we have stated...

October 19, 2020
Humanigen Logo
Markets

HCW starts Humanigen at buy; PT $31

H.C. Wainwright launched coverage of Humanigen (NASDAQ:HGEN) with a “buy” rating and price target of $31. The stock closed at $12.03 on Oct. 13. The company’s lead asset, lenzilumab, is an antibody targeting...

October 14, 2020
Medicenna Therapeutics
Markets

HCW starts Medicenna Therapeutics at buy; PT $8

H.C. Wainwright initiated coverage of Medicenna Therapeutics (NASDAQ:MDNA) with a “buy” rating and price target of $8. The stock closed at $3.88 on Sept. 8. Medicenna is an immuno-oncology company developing therapies...

September 10, 2020
Corbus Pharmaceuticals
Markets

HCW reduces Corbus Pharma PT to $6 from $24

H.C. Wainwright slashed the price target for Corbus Pharmaceuticals (NASDAQ:CRBP) to $6 from $24 but maintained its “buy” rating after the company’s Phase 3 RESOLVE-1 trial of lenabasum in cutaneous systemic sclerosis...

September 9, 2020